Journal of Microbiology and Biotechnology
The Korean Society for Microbiology and Biotechnology publishes the Journal of Microbiology and Biotechnology.

2018 ; Vol.28-12: 2095~2105

AuthorKeji Quan, Zhuang Zhu, Sanjie Cao, Fei Zhang, Chang Miao, Xintian Wen, Xiaobo Huang, Yiping Wen, Rui Wu, Qigui Yan, Yong Huang, Xiaoping Ma, Xinfeng Han, Qin Zhao
Place of dutySichuan Agricultural University, Chengdu, China
TitleEscherichia coli-derived outer membrane vesicles deliver galactose-1-phosphate uridyltransferase and yield partial protection against Actinobacillus pleuropneumoniae in mice
PublicationInfo J. Microbiol. Biotechnol.2018 ; Vol.28-12
AbstractIn our previous studies, we have identified several in vivo-induced antigens and evaluated their potential as subunit vaccine candidates in a murine model, in which the recombinant protein GalT showed the most potent immunogenicity and immunoprotective efficacy against Actinobacillus pleuropneumoniae. To exploit a more efficient way of delivering GalT proteins, in this study, we employed the widely studied E. coli outer membrane vesicles (OMVs) as a platform to deliver GalT protein and performed the vaccine trial using the recombinant GalT-OMVs in murine model. Results revealed that GalT-OMVs could elicit highly specific IgG antibody titer that was comparable with adjuvant GalT group. Significantly higher lymphocyte proliferation and cytokines secretion level were observed in GalT-OMVs group. 87.5% and 50% of mice were protected from lethal dose challenge of A.pleuropneumoniae in active or passive immunization, respectively. Histopathologic and immunohistochemical analysis showed remarkably reduced pathological changes and infiltration of neutrophils in the lungs of mice immunized with GalT-OMVs after challenge. Taken together, these findings confirm that OMVs can be used as a platform to deliver GalT protein and enhance its immunogenicity to induce both humoral and cellular immune responses in mice.
Full-Text
Key_wordActinobacillus pleuropneumoniae,, GalT protein, OMVs, immunoprotective efficacy
References
  1. Li Y, Cao S, Zhang L, Lau GW, Wen Y, Wu R, et al. 2016. A TolC-like protein of Actinobacillus pleuropneumoniae is involved in antibiotic resistance and biofilm formation. Front. Microbiol. 7: 1618.
    Pubmed CrossRef Pubmed Central
  2. Bosse JT, Soares-Bazzolli DM, Li Y, Wren BW, Tucker AW, Maskell DJ, et al. 2014. The generation of successive unmarked mutations and chromosomal insertion of heterologous genes in Actinobacillus pleuropneumoniae using natural transformation. PLoS One 9: e111252.
    Pubmed CrossRef Pubmed Central
  3. Cuccui J, Terra VS, Bossé JT, Naegeli A, Abouelhadid S, Li Y, et al. 2017. The N-linking glycosylation system from Actinobacillus pleuropneumoniae i s requ ired f or adhesion and has potential use in glycoengineering. Open Biol. 7.
  4. Zhu Z, Zhao Q, Zhao Y, Zhang F, Wen X, Huang X, et al. 2017. Polyamine-binding protein PotD2 is required for stress tolerance and virulence in Actinobacillus pleuropneumoniae. Antonie van Leeuwenhoek 110: 1647-1657.
    Pubmed CrossRef
  5. Sárközi R, Makrai L, Fodor L. 2015. Identification of a proposed new serovar of Actinobacillus pleuropneumoniae:serovar 16. Acta Vet. Hung. 63: 444-450.
    Pubmed CrossRef
  6. Bossé J, Li Y, Sárközi R, Fodor L, Lacouture S, Gottschalk M, et al. 2018. Proposal of serovars 17 and 18 of Actinobacillus pleuropneumoniae based on serological and genotypic analysis. Vet. Microbiol. 217: 1-6.
    Pubmed CrossRef Pubmed Central
  7. Oldfield NJ, Donovan EA, Worrall KE, Wooldridge KG, Langford PR, Rycroft AN, et al. 2008. Identification and characterization of novel antigenic vaccine candidates of Actinobacillus pleuropneumoniae. Vaccine 26: 1942-1954.
    Pubmed CrossRef
  8. Chiang CH, Huang WF, Huang LP, Lin SF, Yang WJ. 2009. Immunogenicity and protective efficacy of ApxIA and ApxIIA DNA vaccine against Actinobacillus pleuropneumoniae lethal challenge in murine model. Vaccine 27: 4565-4570.
    Pubmed CrossRef
  9. Lu YC, Li MC, Chen YM, Chu CY, Lin SF, Yang WJ. 2011. DNA vaccine encoding type IV pilin of Actinobacillus pleuropneumoniae induces strong immune response but confers limited protective efficacy against serotype 2 challenge. Vaccine 29: 7740-7746.
    Pubmed CrossRef
  10. Bei W , He Q , Zhou R, Yan L, H uang H, C hen H. 2 007. Evaluation of immunogenicity and protective efficacy of Actinobacillus pleuropneumoniae HB04C(-) mutant lacking a drug resistance marker in the pigs. Vet. Microbiol. 125: 120-127.
    Pubmed CrossRef
  11. Chen DJ, Langer R. 2010. Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc. Natl. Acad. Sci. USA 107: 3099-3104.
    Pubmed CrossRef Pubmed Central
  12. Abbas AK, Lichtman AH, Pillai S. 2012. Basic Immunology, pp. 36-42. Ed. Saunders.
  13. Schwechheimer C, Kuehn MJ. 2015. Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions. Nat. Rev. Microbiol. 13: 605-619.
    Pubmed CrossRef Pubmed Central
  14. Schertzer JW, Whiteley M. 2012. A bilayer-couple model of bacterial outer membrane vesicle biogenesis. MBio 3: 203-216.
    Pubmed CrossRef Pubmed Central
  15. Kulp A, Kuehn MJ. 2010. Biological functions and biogenesis of secreted bacterial outer membrane vesicles. Annu. Rev. Microbiol. 64: 163-184.
    Pubmed CrossRef Pubmed Central
  16. Mashburn-Warren LM, Whiteley M. 2006. Special delivery:vesicle trafficking in prokaryotes. Mol. Microbiol. 61: 839-846.
    Pubmed CrossRef
  17. Kuehn MJ, Kesty NC. 2005. Bacterial outer membrane vesicles and the host–pathogen interaction. Genes Dev. 19:2645-2655.
    Pubmed CrossRef
  18. Lee EY, Choi DS, Kim KP, Yong SG. 2008. Proteomics in gram-negative bacterial outer membrane vesicles. Mass Spectrom. Rev. 27: 535-555.
    Pubmed CrossRef
  19. Fulsundar S, Harms K, Flaten GE, Johnsen PJ, Chopade BA, Nielsen KM. 2014. Gene transfer potential of outer membrane vesicles of Acinetobacter baylyi and effects of stress on vesiculation. Appl. Environ. Microbiol. 80: 3469-3483.
    Pubmed CrossRef
  20. Yaron S, Kolling GL, Simon L, Matthews KR. 2000. Vesiclemediated transfer of virulence genes from Escherichia coli O157:H7 to other enteric bacteria. Appl. Environ. Microbiol. 66: 4414-4420.
    Pubmed CrossRef
  21. Schooling SR, Beveridge TJ. 2006. Membrane vesicles: an overlooked component of the matrices of biofilms. J. Bacteriol. 188: 5945-5957.
    Pubmed CrossRef
  22. van der Pol L, Stork M, van der Ley P. 2015. Outer membrane vesicles as platform vaccine technology. Biotechnol. J. 10: 1689-1706.
    Pubmed CrossRef
  23. Ellis TN, Kuehn MJ. 2010. Virulence and immunomodulatory roles of bacterial outer membrane vesicles. Microbiol. Mol. Biol. Rev. 74: 81-94.
    Pubmed CrossRef Pubmed Central
  24. Kleijn EDD, Groot RD, Labadie J, Lafeber AB, Dobbelsteen GVD, Alphen LV, et al. 2000. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2–3 and 7–8 years of age. Vaccine 18: 1456-1466.
    CrossRef
  25. Sandbu S, Feiring B, Oster P, Helland OS, Bakke HSW, Næss LM, et al. 2007. Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines. Clin. Vaccine Immunol. 14: 10621069.
    Pubmed CrossRef Pubmed Central
  26. Wai SN, Lindmark B, Söderblom T, Takade A, Westermark M, Oscarsson J, et al. 2003. Vesicle-mediated export and assembly of pore-forming oligomers of the enterobacterial ClyA cytotoxin. Cell 115: 25-35.
    CrossRef
  27. Rappazzo CG, Watkins HC, Guarino CM, Chau A, Lopez JL, Delisa MP, et al. 2016. Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice. Vaccine 34: 1252-1258.
    Pubmed CrossRef
  28. Huang W, Wang S, Yao Y, Xia Y, Yang X, Li K, et al. 2016. Employing Escherichia coli-derived outer membrane vesicles as an antigen delivery platform elicits protective immunity against Acinetobacter baumannii infection. Sci. Rep. 6: 37242.
    Pubmed CrossRef Pubmed Central
  29. Zhang F , Cao S, Z hu Z, Yang Y , Wen X , Chang YF, et al. 2016. Immunoprotective efficacy of six in vivo-induced antigens against Actinobacillus pleuropneumoniae as potential vaccine candidates in murine model. Front. Microbiol. 7: 728732.
    Pubmed CrossRef Pubmed Central
  30. Zhang F, Zhang Y, Wen X, Huang X, Wen Y, Wu R, et al. 2015. Identification of Actinobacillus pleuropneumoniae genes preferentially expressed during infection using in vivoinduced antigen technology (IVIAT). J. Microbiol. Biotechnol. 25: 1606-1613.
    Pubmed CrossRef
  31. Zhang F, Zhao Q, Quan K, Zhu Z, Yang Y, Wen X, et al. 2018. Galactose-1-phosphate uridyltransferase (GalT), an in vivo-induced antigen of Actinobacillus pleuropneumoniae serovar 5b strain L20, provided immunoprotection against serovar 1 strain MS71. PLoS One 13: e0198207.
    Pubmed CrossRef Pubmed Central
  32. Kim J Y, D oody AM, Chen DJ, C remona G H, P u tnam D, Delisa MP. 2008. Engineered bacterial outer membrane vesicles with enhanced functionality. J. Mol. Biol. 380: 51-66.
    Pubmed CrossRef Pubmed Central
  33. Fu S, Zhang M, Xu J, Ou J, Wang Y, Liu H, et al. 2012. Immunogenicity and protective efficacy of recombinant Haemophilus parasuis SH0165 putative outer membrane proteins. Vaccine 31: 347-353.
    Pubmed CrossRef
  34. Li M, Song S, Yang D, Li C, Li G. 2015. Identification of secreted proteins as novel antigenic vaccine candidates of Haemophilus parasuis serovar 5. Vaccine 33: 1695-1701.
    Pubmed CrossRef
  35. Oh Y, Ha Y, Han K, Seo HW, Kang I, Park C, et al. 2013. Expression of leucocyte function-associated antigen-1 and intercellular adhesion molecule-1 in the lungs of pigs infected with Actinobacillus pleuropneumoniae. J. Comp. Pathol. 148: 259-265.
    Pubmed CrossRef
  36. Bachmann MF, Jennings GT. 2010. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10: 787-796.
    Pubmed CrossRef
  37. Mccaig WD, Loving CL, Hughes HR, Brockmeier SL. 2016. Characterization and vaccine potential of outer membrane vesicles produced by Haemophilus parasuis. PLoS One 11:e0149132.
    Pubmed CrossRef Pubmed Central
  38. Stevenson TC, Cywesbentley C, Moeller TD, Weyant KB, Putnam D, Chang YF, et al. 2018. Immunization with outer membrane vesicles displaying conserved surface polysaccharide antigen elicits broadly antimicrobial antibodies. Proc. Natl. Acad. Sci. USA 115: 201718341.
    Pubmed CrossRef Pubmed Central
  39. Asensio CJ, Gaillard ME, Moreno G, Bottero D, Zurita E, Rumbo M, et al. 2011. Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate. Vaccine 29: 1649-1656.
    Pubmed CrossRef
  40. Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, et al. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 14: 195-207.
    Pubmed
  41. Xu K, Zhao Q, Wen X, Wu R, Wen Y, Huang X, et al. 2018. A trivalent Apx-fusion protein delivered by E. coli o u ter membrane vesicles induce protection against Actinobacillus pleuropneumoniae of serotype 1 and 7 challenge in a murine model. PLoS One 13: e0191286.
    Pubmed CrossRef Pubmed Central
  42. Zhao K, D eng X, H e C, Y u e B, W u M . 2013. Pseudomonas aeruginosa outer membrane vesicles modulate host immune responses by targeting the toll-like receptor 4 signaling pathway. Infect. Immun. 81: 4509-4518.
    Pubmed CrossRef Pubmed Central
  43. Fransen F, Stenger RM, Poelen MC, van Dijken HH, Kuipers B, Boog CJ, et al. 2010. Differential effect of TLR2 and TLR4 on the immune response after immunization with a vaccine against Neisseria meningitidis or Bordetella pertussis. PLoS One 5: e15692.
    Pubmed CrossRef Pubmed Central
  44. Chen L, Valentine JL, Huang CJ, Endicott CE, Moeller TD, Rasmussen JA, et al. 2016. Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies. Proc. Natl. Acad. Sci. USA 113: E3609-3618.
    Pubmed CrossRef Pubmed Central
  45. Kim SH, Kim KS, Lee SR, Kim E, Kim MS, Lee EY, et al. 2009. Structural modifications of outer membrane vesicles to refine them as vaccine delivery vehicles. Biochim. Biophys. Acta 1788: 2150-2159.
    Pubmed CrossRef Pubmed Central



Copyright © 2009 by the Korean Society for Microbiology and Biotechnology.
All right reserved. Mail to jmb@jmb.or.kr
Online ISSN: 1738-8872    Print ISSN: 1017-7825    Powered by INFOrang.co., Ltd